Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Valérie Vilgrain, Mohamed Abdel-Rehim, Annie Sibert, Maxime Ronot, Rachida Lebtahi, Laurent Castéra, Gilles Chatellier

ABSTRACT

BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis. While sorafenib is the current recommended treatment for advanced HCC, radioembolisation (RE; also called selective internal radiation therapy or SIRT) with yttrium-90 microspheres has shown efficacy in cohort studies. However, there are no head-to-head trials comparing radiation therapy with yttrium-90 microspheres and sorafenib in advanced HCC. The SARAH trial has been designed to compare the efficacy and safety of sorafenib therapy and RE using yttrium-90 resin microspheres (SIR-Spheres™; Sirtex Medical Limited, North Sydney, Australia) in patients with advanced HCC. Quality of life (QoL) and cost-effectiveness will also be compared between therapies. METHODS/DESIGN: SARAH is a prospective, randomised, controlled, open-label, multicentre trial comparing the efficacy of RE with sorafenib in the treatment of patients with advanced HCC. The trial aims to recruit adults with a life expectancy of >3 months, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1, and: advanced HCC according to the Barcelona criteria (stage C) or recurrent HCC after surgical or thermoablative treatment who are not eligible for surgical resection, liver transplantation or thermal ablation; or two rounds of failed chemoembolisation. Patients will be randomised 1:1 to receive either RE or sorafenib 400 mg twice daily. All patients will be monitored for between 12 and 48 months following start of treatment. The primary endpoint of the SARAH trial is overall survival (OS). Secondary endpoints include: adverse events, progression-free survival at 6 months; tumour response rate; general or liver disease-specific QoL scores; and cost of each treatment strategy. Assuming an increase in median OS of 4 months with RE versus sorafenib therapy, randomising at least 400 patients (200 in each treatment arm) will be sufficient for 80% power and a bilateral alpha risk of 5%; therefore, 440 patients will be enrolled to allow for 10% loss of patients due to ineligibility. DISCUSSION: The SARAH trial is the first randomised head-to-head study to compare RE with sorafenib in advanced HCC, and will establish the potential role of RE in HCC treatment guidelines. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01482442, first received 28 November 2011. More... »

PAGES

474

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1745-6215-15-474

DOI

http://dx.doi.org/10.1186/1745-6215-15-474

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037557459

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25472660


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Hepatocellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Costs", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Embolization, Therapeutic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "France", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Microspheres", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Yttrium Radioisotopes", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Paris Diderot University", 
          "id": "https://www.grid.ac/institutes/grid.7452.4", 
          "name": [
            "Department of Radiology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France", 
            "University Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France, INSERM U1149, Centre de Recherche de l\u2019Inflammation (CRI), 16 rue Henri Huchard, 75018, Paris, France", 
            "the SARAH trial group, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vilgrain", 
        "givenName": "Val\u00e9rie", 
        "id": "sg:person.0761705775.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761705775.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Assistance Publique -Hopitaux De Paris", 
          "id": "https://www.grid.ac/institutes/grid.50550.35", 
          "name": [
            "Department of Radiology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abdel-Rehim", 
        "givenName": "Mohamed", 
        "id": "sg:person.01013766312.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013766312.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Assistance Publique -Hopitaux De Paris", 
          "id": "https://www.grid.ac/institutes/grid.50550.35", 
          "name": [
            "Department of Radiology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sibert", 
        "givenName": "Annie", 
        "id": "sg:person.0626003100.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626003100.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Paris Diderot University", 
          "id": "https://www.grid.ac/institutes/grid.7452.4", 
          "name": [
            "Department of Radiology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France", 
            "University Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France, INSERM U1149, Centre de Recherche de l\u2019Inflammation (CRI), 16 rue Henri Huchard, 75018, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ronot", 
        "givenName": "Maxime", 
        "id": "sg:person.01025534354.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025534354.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Assistance Publique -Hopitaux De Paris", 
          "id": "https://www.grid.ac/institutes/grid.50550.35", 
          "name": [
            "Department of Nuclear Medicine, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 100 boulevard General Leclerc, 92118, Hauts-de-Seine, Clichy, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lebtahi", 
        "givenName": "Rachida", 
        "id": "sg:person.0621226525.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621226525.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Paris Diderot University", 
          "id": "https://www.grid.ac/institutes/grid.7452.4", 
          "name": [
            "Department of Hepatology, Assistance Publique, H\u00f4pitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 100 boulevard General Leclerc, 92118, Hauts-de-Seine, Clichy, France", 
            "University Paris Diderot, Sorbonne Paris Cit\u00e9, 5 rue Thomas Mann, 75013, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cast\u00e9ra", 
        "givenName": "Laurent", 
        "id": "sg:person.0631670105.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631670105.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Paris Descartes University", 
          "id": "https://www.grid.ac/institutes/grid.10992.33", 
          "name": [
            "Assistance Publique, H\u00f4pitaux de Paris, APHP, H\u00f4pital Europ\u00e9en Georges Pompidou, URC, 20 rue Leblanc, 75015, Paris, France", 
            "INSERM, Centre d\u2019Investigation \u00c9pid\u00e9miologique 4 (CIE4), 80 rue Lecourbe, 75015, Paris, France", 
            "Sorbonne Paris Cit\u00e9, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris-Descartes, 12 rue de l'Ecole de M\u00e9decine, 75006, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chatellier", 
        "givenName": "Gilles", 
        "id": "sg:person.0610327425.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610327425.04"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1053/j.gastro.2009.09.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003442138"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/lt.22434", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003964451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.21980", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012076894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-011-1753-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012147791", 
          "https://doi.org/10.1007/s00280-011-1753-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cct.2009.08.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012763140"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1226-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014381903", 
          "https://doi.org/10.1007/s00280-009-1226-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1226-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014381903", 
          "https://doi.org/10.1007/s00280-009-1226-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2013-0114", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014890838"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jso.20609", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017230735"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2013.12.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018387939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(08)70285-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018829845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.23944", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019162732"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.23944", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019162732"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jvir.2007.07.016", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021011178"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00330-008-1211-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024345371", 
          "https://doi.org/10.1007/s00330-008-1211-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2006.05.065", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028312901"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(08)70003-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031125262"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2010.1672", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033887880"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0168-8278(09)60780-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035571428"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.gastro.2008.02.090", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038242669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000343091", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038427252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.37.1021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041287255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2009.06.069", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042012604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.24451", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042501738"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1994.436", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042684896", 
          "https://doi.org/10.1038/bjc.1994.436"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1994.436", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042684896", 
          "https://doi.org/10.1038/bjc.1994.436"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.26014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044188627"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2004.06.033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045614635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2010-s4-05", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047436237"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0360-3016(97)00818-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050128451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djn134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050426018"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jhep.2011.12.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051138497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0708857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053513212"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2307/2532572", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069977982"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/etm.2012.569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071503303"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis. While sorafenib is the current recommended treatment for advanced HCC, radioembolisation (RE; also called selective internal radiation therapy or SIRT) with yttrium-90 microspheres has shown efficacy in cohort studies. However, there are no head-to-head trials comparing radiation therapy with yttrium-90 microspheres and sorafenib in advanced HCC. The SARAH trial has been designed to compare the efficacy and safety of sorafenib therapy and RE using yttrium-90 resin microspheres (SIR-Spheres\u2122; Sirtex Medical Limited, North Sydney, Australia) in patients with advanced HCC. Quality of life (QoL) and cost-effectiveness will also be compared between therapies.\nMETHODS/DESIGN: SARAH is a prospective, randomised, controlled, open-label, multicentre trial comparing the efficacy of RE with sorafenib in the treatment of patients with advanced HCC. The trial aims to recruit adults with a life expectancy of >3 months, Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1, and: advanced HCC according to the Barcelona criteria (stage C) or recurrent HCC after surgical or thermoablative treatment who are not eligible for surgical resection, liver transplantation or thermal ablation; or two rounds of failed chemoembolisation. Patients will be randomised 1:1 to receive either RE or sorafenib 400 mg twice daily. All patients will be monitored for between 12 and 48 months following start of treatment. The primary endpoint of the SARAH trial is overall survival (OS). Secondary endpoints include: adverse events, progression-free survival at 6 months; tumour response rate; general or liver disease-specific QoL scores; and cost of each treatment strategy. Assuming an increase in median OS of 4 months with RE versus sorafenib therapy, randomising at least 400 patients (200 in each treatment arm) will be sufficient for 80% power and a bilateral alpha risk of 5%; therefore, 440 patients will be enrolled to allow for 10% loss of patients due to ineligibility.\nDISCUSSION: The SARAH trial is the first randomised head-to-head study to compare RE with sorafenib in advanced HCC, and will establish the potential role of RE in HCC treatment guidelines.\nTRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01482442, first received 28 November 2011.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1745-6215-15-474", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297400", 
        "issn": [
          "1468-6708", 
          "1745-6215"
        ], 
        "name": "Trials", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "Radioembolisation with yttrium\u201290 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial", 
    "pagination": "474", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b2e8fa22607d0fae3de7bcc9a5fdc2ed944f26b055bbf955cdb59a9651ae6620"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25472660"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101263253"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1745-6215-15-474"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037557459"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1745-6215-15-474", 
      "https://app.dimensions.ai/details/publication/pub.1037557459"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1745-6215-15-474"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-474'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-474'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-474'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1745-6215-15-474'


 

This table displays all metadata directly associated to this object as RDF triples.

311 TRIPLES      21 PREDICATES      83 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1745-6215-15-474 schema:about N075ba275679d4dc388528f66797c59a3
2 N0dfda348ac0a4cdc927a4b264c770a15
3 N1749936f83bd48748ec6f1f25a12e8f2
4 N1fb13c211889484ea2a5fb4e23051972
5 N2159e1ca567b42d8b67962f03036bd5b
6 N2fa2e4cd2ed245419cb4971bf46b4c89
7 N32f51acf31ed463696812973ae6bf3be
8 N393560f175ff468ca63b7cd941771c7f
9 N41995ddf069b42c4afa0d995e48ffdba
10 N4a4c0c8ad12d4cc29ac9c3b9fe82c0ee
11 N6b8f79ddc7234425ba58456a0ec680e9
12 N9739d2930cb34e7c8012f5bdcdbfe769
13 Na11e281723e9479580d729cbd98bb2eb
14 Na726dfa84f8f41198781f9bd221be4d5
15 Naa7ff23965ef422d82ca9b2884ad572f
16 Nb54d36a8195e419ba7604329dc087e09
17 Nb583708079394f2d9131e16ac0103e08
18 Nbb8b29d64547425eb3393f52bd159dd5
19 Ncae13bb43e324b2e9fde6555af1fb05f
20 Nd8a228930be1411f9e5a7033c3b4e9ff
21 Ndfde9fba70a14873af3fb013fd141ba6
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N34a4e110a8854f0cbe9af6d92e2bf538
25 schema:citation sg:pub.10.1007/s00280-009-1226-z
26 sg:pub.10.1007/s00280-011-1753-2
27 sg:pub.10.1007/s00330-008-1211-7
28 sg:pub.10.1038/bjc.1994.436
29 https://doi.org/10.1001/jama.2010.1672
30 https://doi.org/10.1002/hep.21980
31 https://doi.org/10.1002/hep.23944
32 https://doi.org/10.1002/hep.24451
33 https://doi.org/10.1002/hep.26014
34 https://doi.org/10.1002/jso.20609
35 https://doi.org/10.1002/lt.22434
36 https://doi.org/10.1016/j.cct.2009.08.002
37 https://doi.org/10.1016/j.critrevonc.2013.12.013
38 https://doi.org/10.1016/j.ejca.2004.06.033
39 https://doi.org/10.1016/j.ijrobp.2006.05.065
40 https://doi.org/10.1016/j.ijrobp.2009.06.069
41 https://doi.org/10.1016/j.jhep.2011.12.001
42 https://doi.org/10.1016/j.jvir.2007.07.016
43 https://doi.org/10.1016/s0168-8278(09)60780-7
44 https://doi.org/10.1016/s0360-3016(97)00818-3
45 https://doi.org/10.1016/s1470-2045(08)70003-2
46 https://doi.org/10.1016/s1470-2045(08)70285-7
47 https://doi.org/10.1053/j.gastro.2008.02.090
48 https://doi.org/10.1053/j.gastro.2009.09.006
49 https://doi.org/10.1056/nejmoa0708857
50 https://doi.org/10.1093/jnci/92.3.205
51 https://doi.org/10.1093/jnci/djn134
52 https://doi.org/10.1159/000343091
53 https://doi.org/10.1200/jco.2011.37.1021
54 https://doi.org/10.1634/theoncologist.2010-s4-05
55 https://doi.org/10.1634/theoncologist.2013-0114
56 https://doi.org/10.2307/2532572
57 https://doi.org/10.3892/etm.2012.569
58 schema:datePublished 2014-12
59 schema:datePublishedReg 2014-12-01
60 schema:description BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis. While sorafenib is the current recommended treatment for advanced HCC, radioembolisation (RE; also called selective internal radiation therapy or SIRT) with yttrium-90 microspheres has shown efficacy in cohort studies. However, there are no head-to-head trials comparing radiation therapy with yttrium-90 microspheres and sorafenib in advanced HCC. The SARAH trial has been designed to compare the efficacy and safety of sorafenib therapy and RE using yttrium-90 resin microspheres (SIR-Spheres™; Sirtex Medical Limited, North Sydney, Australia) in patients with advanced HCC. Quality of life (QoL) and cost-effectiveness will also be compared between therapies. METHODS/DESIGN: SARAH is a prospective, randomised, controlled, open-label, multicentre trial comparing the efficacy of RE with sorafenib in the treatment of patients with advanced HCC. The trial aims to recruit adults with a life expectancy of >3 months, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1, and: advanced HCC according to the Barcelona criteria (stage C) or recurrent HCC after surgical or thermoablative treatment who are not eligible for surgical resection, liver transplantation or thermal ablation; or two rounds of failed chemoembolisation. Patients will be randomised 1:1 to receive either RE or sorafenib 400 mg twice daily. All patients will be monitored for between 12 and 48 months following start of treatment. The primary endpoint of the SARAH trial is overall survival (OS). Secondary endpoints include: adverse events, progression-free survival at 6 months; tumour response rate; general or liver disease-specific QoL scores; and cost of each treatment strategy. Assuming an increase in median OS of 4 months with RE versus sorafenib therapy, randomising at least 400 patients (200 in each treatment arm) will be sufficient for 80% power and a bilateral alpha risk of 5%; therefore, 440 patients will be enrolled to allow for 10% loss of patients due to ineligibility. DISCUSSION: The SARAH trial is the first randomised head-to-head study to compare RE with sorafenib in advanced HCC, and will establish the potential role of RE in HCC treatment guidelines. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT01482442, first received 28 November 2011.
61 schema:genre research_article
62 schema:inLanguage en
63 schema:isAccessibleForFree true
64 schema:isPartOf N37d36562abd04e10b03e5c2e91744422
65 N532fa58c572b4c8da5c6c2bbe569b51a
66 sg:journal.1297400
67 schema:name Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial
68 schema:pagination 474
69 schema:productId N3fbc4e23d1ae40f9a37ba0f27d7bcdfc
70 N5b55abdc349e403a8b2a2cccc87e3e6b
71 N73948d2105164e329eb282a39cdbc1c5
72 Nc179a633a59f452aab3d493bab1ca1ea
73 Neff9cec68b254833894dd36e918cfaa7
74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037557459
75 https://doi.org/10.1186/1745-6215-15-474
76 schema:sdDatePublished 2019-04-10T14:10
77 schema:sdLicense https://scigraph.springernature.com/explorer/license/
78 schema:sdPublisher N6055c747b32f430caad29a60b9ffe6fc
79 schema:url http://link.springer.com/10.1186%2F1745-6215-15-474
80 sgo:license sg:explorer/license/
81 sgo:sdDataset articles
82 rdf:type schema:ScholarlyArticle
83 N075ba275679d4dc388528f66797c59a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name France
85 rdf:type schema:DefinedTerm
86 N0dfda348ac0a4cdc927a4b264c770a15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Antineoplastic Agents
88 rdf:type schema:DefinedTerm
89 N1749936f83bd48748ec6f1f25a12e8f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Disease Progression
91 rdf:type schema:DefinedTerm
92 N1fb13c211889484ea2a5fb4e23051972 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Cost-Benefit Analysis
94 rdf:type schema:DefinedTerm
95 N2159e1ca567b42d8b67962f03036bd5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Embolization, Therapeutic
97 rdf:type schema:DefinedTerm
98 N264cd4aac2cf4477a442a29115d9867c rdf:first sg:person.0610327425.04
99 rdf:rest rdf:nil
100 N2fa2e4cd2ed245419cb4971bf46b4c89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Research Design
102 rdf:type schema:DefinedTerm
103 N32f51acf31ed463696812973ae6bf3be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Time Factors
105 rdf:type schema:DefinedTerm
106 N34a4e110a8854f0cbe9af6d92e2bf538 rdf:first sg:person.0761705775.52
107 rdf:rest Nfc8b59414c9740d098f8ef59a17cb52f
108 N37d36562abd04e10b03e5c2e91744422 schema:volumeNumber 15
109 rdf:type schema:PublicationVolume
110 N393560f175ff468ca63b7cd941771c7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Carcinoma, Hepatocellular
112 rdf:type schema:DefinedTerm
113 N3fbc4e23d1ae40f9a37ba0f27d7bcdfc schema:name readcube_id
114 schema:value b2e8fa22607d0fae3de7bcc9a5fdc2ed944f26b055bbf955cdb59a9651ae6620
115 rdf:type schema:PropertyValue
116 N41995ddf069b42c4afa0d995e48ffdba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Prospective Studies
118 rdf:type schema:DefinedTerm
119 N4a4c0c8ad12d4cc29ac9c3b9fe82c0ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Protein Kinase Inhibitors
121 rdf:type schema:DefinedTerm
122 N532fa58c572b4c8da5c6c2bbe569b51a schema:issueNumber 1
123 rdf:type schema:PublicationIssue
124 N5b55abdc349e403a8b2a2cccc87e3e6b schema:name doi
125 schema:value 10.1186/1745-6215-15-474
126 rdf:type schema:PropertyValue
127 N5e7a462815f942e8aab177f534569771 rdf:first sg:person.0631670105.90
128 rdf:rest N264cd4aac2cf4477a442a29115d9867c
129 N6055c747b32f430caad29a60b9ffe6fc schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 N6b8f79ddc7234425ba58456a0ec680e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Quality of Life
133 rdf:type schema:DefinedTerm
134 N73948d2105164e329eb282a39cdbc1c5 schema:name nlm_unique_id
135 schema:value 101263253
136 rdf:type schema:PropertyValue
137 N9739d2930cb34e7c8012f5bdcdbfe769 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Liver Neoplasms
139 rdf:type schema:DefinedTerm
140 Na11e281723e9479580d729cbd98bb2eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Microspheres
142 rdf:type schema:DefinedTerm
143 Na726dfa84f8f41198781f9bd221be4d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Phenylurea Compounds
145 rdf:type schema:DefinedTerm
146 Naa7ff23965ef422d82ca9b2884ad572f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Niacinamide
148 rdf:type schema:DefinedTerm
149 Nad549866d7404ed8a4313441bd3b45be rdf:first sg:person.0621226525.47
150 rdf:rest N5e7a462815f942e8aab177f534569771
151 Nb54d36a8195e419ba7604329dc087e09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Yttrium Radioisotopes
153 rdf:type schema:DefinedTerm
154 Nb583708079394f2d9131e16ac0103e08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Treatment Outcome
156 rdf:type schema:DefinedTerm
157 Nbb8b29d64547425eb3393f52bd159dd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Clinical Protocols
159 rdf:type schema:DefinedTerm
160 Nc179a633a59f452aab3d493bab1ca1ea schema:name pubmed_id
161 schema:value 25472660
162 rdf:type schema:PropertyValue
163 Ncae13bb43e324b2e9fde6555af1fb05f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Disease-Free Survival
165 rdf:type schema:DefinedTerm
166 Nd8a228930be1411f9e5a7033c3b4e9ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Humans
168 rdf:type schema:DefinedTerm
169 Ndfde9fba70a14873af3fb013fd141ba6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Drug Costs
171 rdf:type schema:DefinedTerm
172 Ned14183060804a9bbdc2482adda763b3 rdf:first sg:person.01025534354.12
173 rdf:rest Nad549866d7404ed8a4313441bd3b45be
174 Neff9cec68b254833894dd36e918cfaa7 schema:name dimensions_id
175 schema:value pub.1037557459
176 rdf:type schema:PropertyValue
177 Nfc8b59414c9740d098f8ef59a17cb52f rdf:first sg:person.01013766312.46
178 rdf:rest Nff7e077e6e3b49778dcc8f810d22004f
179 Nff7e077e6e3b49778dcc8f810d22004f rdf:first sg:person.0626003100.28
180 rdf:rest Ned14183060804a9bbdc2482adda763b3
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
185 schema:name Oncology and Carcinogenesis
186 rdf:type schema:DefinedTerm
187 sg:journal.1297400 schema:issn 1468-6708
188 1745-6215
189 schema:name Trials
190 rdf:type schema:Periodical
191 sg:person.01013766312.46 schema:affiliation https://www.grid.ac/institutes/grid.50550.35
192 schema:familyName Abdel-Rehim
193 schema:givenName Mohamed
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013766312.46
195 rdf:type schema:Person
196 sg:person.01025534354.12 schema:affiliation https://www.grid.ac/institutes/grid.7452.4
197 schema:familyName Ronot
198 schema:givenName Maxime
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025534354.12
200 rdf:type schema:Person
201 sg:person.0610327425.04 schema:affiliation https://www.grid.ac/institutes/grid.10992.33
202 schema:familyName Chatellier
203 schema:givenName Gilles
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610327425.04
205 rdf:type schema:Person
206 sg:person.0621226525.47 schema:affiliation https://www.grid.ac/institutes/grid.50550.35
207 schema:familyName Lebtahi
208 schema:givenName Rachida
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0621226525.47
210 rdf:type schema:Person
211 sg:person.0626003100.28 schema:affiliation https://www.grid.ac/institutes/grid.50550.35
212 schema:familyName Sibert
213 schema:givenName Annie
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626003100.28
215 rdf:type schema:Person
216 sg:person.0631670105.90 schema:affiliation https://www.grid.ac/institutes/grid.7452.4
217 schema:familyName Castéra
218 schema:givenName Laurent
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0631670105.90
220 rdf:type schema:Person
221 sg:person.0761705775.52 schema:affiliation https://www.grid.ac/institutes/grid.7452.4
222 schema:familyName Vilgrain
223 schema:givenName Valérie
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761705775.52
225 rdf:type schema:Person
226 sg:pub.10.1007/s00280-009-1226-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1014381903
227 https://doi.org/10.1007/s00280-009-1226-z
228 rdf:type schema:CreativeWork
229 sg:pub.10.1007/s00280-011-1753-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012147791
230 https://doi.org/10.1007/s00280-011-1753-2
231 rdf:type schema:CreativeWork
232 sg:pub.10.1007/s00330-008-1211-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024345371
233 https://doi.org/10.1007/s00330-008-1211-7
234 rdf:type schema:CreativeWork
235 sg:pub.10.1038/bjc.1994.436 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042684896
236 https://doi.org/10.1038/bjc.1994.436
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1001/jama.2010.1672 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033887880
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1002/hep.21980 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012076894
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1002/hep.23944 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019162732
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1002/hep.24451 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042501738
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1002/hep.26014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044188627
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1002/jso.20609 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017230735
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1002/lt.22434 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003964451
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1016/j.cct.2009.08.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012763140
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1016/j.critrevonc.2013.12.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018387939
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1016/j.ejca.2004.06.033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045614635
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1016/j.ijrobp.2006.05.065 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028312901
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1016/j.ijrobp.2009.06.069 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042012604
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1016/j.jhep.2011.12.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051138497
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1016/j.jvir.2007.07.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021011178
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1016/s0168-8278(09)60780-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035571428
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1016/s0360-3016(97)00818-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050128451
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1016/s1470-2045(08)70003-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031125262
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1016/s1470-2045(08)70285-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018829845
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1053/j.gastro.2008.02.090 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038242669
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1053/j.gastro.2009.09.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003442138
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1056/nejmoa0708857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053513212
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1093/jnci/djn134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050426018
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1159/000343091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038427252
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1200/jco.2011.37.1021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041287255
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1634/theoncologist.2010-s4-05 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047436237
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1634/theoncologist.2013-0114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014890838
291 rdf:type schema:CreativeWork
292 https://doi.org/10.2307/2532572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069977982
293 rdf:type schema:CreativeWork
294 https://doi.org/10.3892/etm.2012.569 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071503303
295 rdf:type schema:CreativeWork
296 https://www.grid.ac/institutes/grid.10992.33 schema:alternateName Paris Descartes University
297 schema:name Assistance Publique, Hôpitaux de Paris, APHP, Hôpital Européen Georges Pompidou, URC, 20 rue Leblanc, 75015, Paris, France
298 INSERM, Centre d’Investigation Épidémiologique 4 (CIE4), 80 rue Lecourbe, 75015, Paris, France
299 Sorbonne Paris Cité, Faculté de Médecine, Université Paris-Descartes, 12 rue de l'Ecole de Médecine, 75006, Paris, France
300 rdf:type schema:Organization
301 https://www.grid.ac/institutes/grid.50550.35 schema:alternateName Assistance Publique -Hopitaux De Paris
302 schema:name Department of Nuclear Medicine, Assistance Publique, Hôpitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 100 boulevard General Leclerc, 92118, Hauts-de-Seine, Clichy, France
303 Department of Radiology, Assistance Publique, Hôpitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France
304 rdf:type schema:Organization
305 https://www.grid.ac/institutes/grid.7452.4 schema:alternateName Paris Diderot University
306 schema:name Department of Hepatology, Assistance Publique, Hôpitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 100 boulevard General Leclerc, 92118, Hauts-de-Seine, Clichy, France
307 Department of Radiology, Assistance Publique, Hôpitaux de Paris, APHP, University Hospitals Paris Nord Val de Seine, Beaujon, 92118, Hauts-de-Seine, 100 boulevard General LeclercClichy, France
308 University Paris Diderot, Sorbonne Paris Cité, 5 rue Thomas Mann, 75013, Paris, France
309 University Paris Diderot, Sorbonne Paris Cité, Paris, France, INSERM U1149, Centre de Recherche de l’Inflammation (CRI), 16 rue Henri Huchard, 75018, Paris, France
310 the SARAH trial group, France
311 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...